Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study observed sustained hair regrowth in some patients with alopecia areata and improvement in vitiligo symptoms, indicating a potential role for dupilumab in treating these conditions, particularly when associated with atopic dermatitis.

This study evaluated Tridax procumbens extracts for their in-vitro alpha amylase inhibitory activity compared to standard antidiabetic agents, suggesting potential benefits for diabetes management.

In this case report, a patient with severe atopic dermatitis experienced significant improvement with dupilumab after other treatments, including immunosuppressive agents, failed to control the disease.

This case report observed that an integrated Shodhana-Shamana treatment protocol effectively managed treatment-resistant Ekakustha (plaque psoriasis), resulting in complete symptom resolution and no relapse at follow-up.

This report describes a case of acute localised exanthematous pustulosis in a 19-year-old boy after using amoxicillin-clavulanic acid, with new dermoscopic features identified.

This case report details the occurrence of paroxysmal nocturnal haemoglobinuria in a 19-year-old woman with systemic lupus erythematosus to raise clinician awareness of this rare association.

This study found that clindamycin-loaded PHA nanoparticles showed potent antibacterial effects against MRSA and enhanced wound healing in a mouse model of MRSA-infected wounds, indicating their potential as a novel treatment for these infections.

This article hypothesizes that apremilast, a phosphodiesterase 4 inhibitor, could be a targeted treatment for alopecia areata due to its ability to suppress interferon-gamma production, but reports no new clinical results.

This source reports that tofacitinib and ruxolitinib showed potential efficacy and acceptable safety profiles in treating various autoimmune disorders, including alopecia areata and psoriasis, based on a review of clinical studies, while recommending physicians consider the individual risks and benefits.

This review examines the adverse skin reactions associated with antipsychotic medications and reports no new clinical findings, but suggests discussing management strategies to improve patient compliance.

This case report describes an 18-year-old girl with systemic lupus erythematosus who developed lupus pneumonitis, initially misdiagnosed as tuberculosis, and responded dramatically to corticosteroid treatment.

In this study, the researchers observed that the severity of capecitabine-induced hand-foot syndrome in advanced gastric cancer patients was not linked to the IVS14+1G→A mutation in the DPYD gene.

This case report details a rare instance of a young male with coexisting autoimmune polyendocrine syndrome type 2 and anti-GAD65 antibody-associated stiff person syndrome, where symptoms improved by adding intravenous immunoglobulin therapy, emphasizing the importance of awareness for early diagnosis and treatment.

This study found that POD-loaded solid lipid nanoparticles using 0.5% poloxamer 188 and 1.5% soybean lecithin (P-SLN) improved epidermal targeting and POD accumulation in porcine skin compared to traditional tincture.

This study found that a topical cream containing PTH (7–34) significantly stimulated hair growth in hairless mice.

This study found that mimicking the XPD point mutation in mice resulted in trichothiodystrophy-like symptoms, supporting the role of basal transcription and DNA repair defects in the disease.

This study found that overexpression of PTHrP in mice chondrocytes led to short-limbed dwarfism and delays in endochondral ossification, highlighting PTHrP's role in inhibiting chondrocyte differentiation.

Riboflavin helps heal bed sores, inositol aids skin diseases, and calcium pantothenate doesn't prevent gray hair.

This study found that mutations in the TMPRSS6 gene affect the ability of matriptase-2 to inhibit hepcidin, which may impact the molecular pathogenesis of iron-refractory iron-deficiency anemia.

This study reports that diphenylcyclopropenone topical immunotherapy resulted in any hair regrowth for 69% of patients with alopecia areata, but with common side effects including mild to severe contact dermatitis.

In this study, pioglitazone treatment in patients with lichen planopilaris showed limited success, with significant improvement seen in only a minority of cases.

This case study highlights the complexity of managing autoimmune polyglandular syndrome type 1, emphasizing the need for thorough clinical history, high suspicion for early diagnosis, and continuous long-term follow-up.

In this case report, two female patients with refractory systemic lupus erythematosus showed significant improvement after treatment with the JAK inhibitor upadacitinib, indicating potential as a promising option for difficult cases, although further research is needed to confirm its broader safety and efficacy.

Docetaxel, a chemotherapy drug, was reported to cause psoriasis in a patient for the first time.

This study developed a 3D bioprinted skin model to mimic pemphigus vulgaris, providing a tool to study disease mechanisms and test targeted therapies by reproducing the architecture and pathogenic disruptions of native skin.

This case report describes a cat with localized scleroderma (morphea-like) that did not show clinical resolution or spontaneous remission after treatment, differing from previously documented cases.

This case report describes a potential drug-induced localized scleroderma in a Persian cat following the application of a 'spot-on' treatment.

Deuruxolitinib is generally safe for treating alopecia areata.

This review found that oral JAK inhibitors, used off-label in various inflammatory skin disorders, often resulted in rapid and sustained clinical improvements with acceptable safety over several months, although the evidence is drawn from case-based reports.

In this case report, a woman with Graham-Little-Piccardi-Lassueur Syndrome and hidradenitis suppurativa showed significant improvements in both conditions after six months of treatment with tofacitinib, a Janus Kinase inhibitor, with no recurrence or adverse events noted during a two-year follow-up.